Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Total Valuation
Viridian Therapeutics has a market cap or net worth of $3.00B. The enterprise value is $2.17B.
Market Cap$3.00B
Enterprise Value$2.17B
Share Statistics
Viridian Therapeutics has 102,206,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding102,206,570
Owned by Insiders4.13%
Owned by Institutions14.85%
Financial Efficiency
Viridian Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.85%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.85%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee495.45K
Profits Per Employee-2.40M
Employee Count143
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viridian Therapeutics is ―. Viridian Therapeutics’s PEG ratio is -0.00141.
PE Ratio―
PS Ratio37.25
PB Ratio3.65
Price to Fair Value3.65
Price to FCF-9.53
Price to Operating Cash Flow-9.01
PEG Ratio-0.00141
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 70.85M and earned -342.60M in profits. Earnings per share was -221.65.
Revenue70.85M
Gross Profit0.00
Operating Income-363.39M
Pretax Income-342.60M
Net Income-342.60M
EBITDA-337.65M
Earnings Per Share (EPS)-221.65
Cash Flow
In the last 12 months, operating cash flow was -276.39M and capital expenditures -495.00K, giving a free cash flow of -276.89M billion.
Operating Cash Flow-276.39M
Free Cash Flow-276.89M
Free Cash Flow per Share-2.71
Dividends & Yields
Viridian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.33
52-Week Price Change103.89%
50-Day Moving Average31.08
200-Day Moving Average22.92
Relative Strength Index (RSI)46.62
Average Volume (3m)814.59K
Important Dates
Viridian Therapeutics upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Viridian Therapeutics as a current ratio of 12.65, with Debt / Equity ratio of 0.00%
Current Ratio12.65
Quick Ratio12.65
Debt to Market Cap0.00
Net Debt to EBITDA0.63
Interest Coverage Ratio-73.44
Taxes
In the past 12 months, Viridian Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viridian Therapeutics EV to EBITDA ratio is -7.19, with an EV/FCF ratio of -8.76.
EV to Sales34.25
EV to EBITDA-7.19
EV to Free Cash Flow-8.76
EV to Operating Cash Flow-8.78
Balance Sheet
Viridian Therapeutics has $874.65M in cash and marketable securities with $0.00 in debt, giving a net cash position of $874.65M billion.
Cash & Marketable Securities$874.65M
Total Debt$0.00
Net Cash$874.65M
Net Cash Per Share$8.56
Tangible Book Value Per Share$8.52
Margins
Gross margin is 0.00%, with operating margin of -512.91%, and net profit margin of -483.57%.
Gross Margin0.00%
Operating Margin-512.91%
Pretax Margin-483.57%
Net Profit Margin-483.57%
EBITDA Margin-476.58%
EBIT Margin-476.58%
Analyst Forecast
The average price target for Viridian Therapeutics is $41.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$41.70
Price Target Upside41.93% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast23340.07%
EPS Growth Forecast18.06%